Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 8 Publications

7 Customer Reviews

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    (a) Westernblot analysis of the whole cell lysate from WT-MTEC, KO-MTEC and 1601 treated with or without Nutlin-3a (15 μM for MTEC) with antibodies as indicated.

    Int J Cancer. 2019, 144(4):777-787. Nutlin-3a purchased from Selleck.

  • Protein expression of p53, TAZ and CYP24A1 were detected by western blot after treatment with Nutlin 3a in CCLP-1.

    Cancer Lett, 2016, 381(2):370-9. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • C) Control-threated cells show an strong nuclear expression of MDM2 and predominantly cytoplasmic localization of FOXM1. D) After treatment with nutlin-3a, the MDM2 immunoreactivity shifted to the perinuclear space indicating a de novo 952 MDM2 synthesis as result of increased p53 activity. In those cells, FOXM1 expression is lost due to p53 activation.

    Neuroendocrinology, 2018, 107(1):1-23. Nutlin-3a purchased from Selleck.

    Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NGD5UJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwNkGyN|ch|ryP NHT1V2RUSU6JRWK=
H4 M1XSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m2cmlEPTB;MD62OlI5KM7:TR?= M4XncXNCVkeHUh?=
PA-1 M3nsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLZTWM2OD1yLki3NFk3KM7:TR?= MX\TRW5ITVJ?
NKM-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrXTWM2OD1zLkC0PVMyKM7:TR?= NHnS[FFUSU6JRWK=
NEC8 M1HN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHITWM2OD1zLkKxOVczKM7:TR?= MXXTRW5ITVJ?
EoL-1-cell MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPMXXlCUUN3ME2xMlI3PzBzIN88US=> MVzTRW5ITVJ?
K5 NVLjR3NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fhN2lEPTB;MT60NlA4OiEQvF2= NFvneYJUSU6JRWK=
QIMR-WIL M1zRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwNkC4OVQh|ryP NUD4SHdnW0GQR1XS
MOLT-16 M3X1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fWZmlEPTB;MT63PFYxPCEQvF2= NGT3W5RUSU6JRWK=
CHP-212 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TIcWlEPTB;MT64NVM3QSEQvF2= NXzXb2JNW0GQR1XS
CTB-1 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjLdGk4UUN3ME2yMlAzOjR4IN88US=> NIXJNI1USU6JRWK=
MOLT-4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHflR4FKSzVyPUKuN|I5PTNizszN NFHXenpUSU6JRWK=
A101D MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\rR2lEPTB;Mj6zOVAyKM7:TR?= M1y2RnNCVkeHUh?=
DOHH-2 M1LMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjFZ2dKSzVyPUKuOFIzPzlizszN M4jBPXNCVkeHUh?=
ES4 M1rCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojoTWM2OD1{LkSzNVU2KM7:TR?= MVvTRW5ITVJ?
SW780 M3;GPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DHTmlEPTB;Mj61NFg5OyEQvF2= M1;oc3NCVkeHUh?=
VA-ES-BJ M3[3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPyTnRVUUN3ME2yMlU1OTFizszN Mn7hV2FPT0WU
RPMI-8866 NUG3[JBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XxNWlEPTB;Mj61OlIyPCEQvF2= M2i2b3NCVkeHUh?=
ML-2 M4nKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\jTWM2OD1{LkW2OVc3KM7:TR?= NFXnPZZUSU6JRWK=
MSTO-211H MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLlTWM2OD1{LkW3OFUyKM7:TR?= M1L0d3NCVkeHUh?=
JVM-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwNUmzNlQh|ryP NFPH[5pUSU6JRWK=
A3-KAW MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[2[2lEPTB;Mj62NVgyQCEQvF2= NH3NWWhUSU6JRWK=
DK-MG NWHvSlFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknmTWM2OD1{Lk[yOFcyKM7:TR?= NFjTPHNUSU6JRWK=
LNCaP-Clone-FGC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH3WXJ7UUN3ME2yMlY1OzF6IN88US=> MkDkV2FPT0WU
HT-144 NIGwfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJwNkS1O|ch|ryP M3P1eXNCVkeHUh?=
NB69 Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwNkWzN|Qh|ryP MlzEV2FPT0WU
A172 NVOy[o5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml64TWM2OD1{Lk[3OVg5KM7:TR?= NES4[VJUSU6JRWK=
RS4-11 NUfofHp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwN{K0NFch|ryP NFXzOYlUSU6JRWK=
DU-4475 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf2U3l2UUN3ME2yMlc6PTB{IN88US=> MXHTRW5ITVJ?
SJSA-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwOEK1OVYh|ryP NITMPGxUSU6JRWK=
BV-173 NXv3[JRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nUXmlEPTB;Mj64OFQ{QSEQvF2= M2jIdnNCVkeHUh?=
U-2-OS M1XsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO5UFE4UUN3ME2yMlkyODdizszN M4PFN3NCVkeHUh?=
CHP-134 NHLDfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfMR5NZUUN3ME2yMlk{QDh{IN88US=> MVzTRW5ITVJ?
D-502MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrsPHRKSzVyPUKuPVcyPTRizszN NFOweHRUSU6JRWK=
KS-1 M{HT[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGizcpdKSzVyPUOuNFE3OjNizszN MWrTRW5ITVJ?
A204 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvGPHVYUUN3ME2zMlA2PTh6IN88US=> M1rNTnNCVkeHUh?=
KGN NWfzOVY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13VRmlEPTB;Mz6wPFQ6PiEQvF2= MXvTRW5ITVJ?
NCI-H292 M3zqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTNwMUKwNlgh|ryP M3PObXNCVkeHUh?=
CAKI-1 M1HIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O0XGlEPTB;Mz6xNlY6PCEQvF2= NFW4PYFUSU6JRWK=
C2BBe1 NYGwPY91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PibWlEPTB;Mz6xO|AzPiEQvF2= NGXPN2pUSU6JRWK=
NB10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTNwMkC5OlYh|ryP MYXTRW5ITVJ?
MHH-NB-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDNSmRKSzVyPUOuNlY5OjdizszN NUDGbGVkW0GQR1XS
NCI-SNU-1 M1rMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTNwMke4OFMh|ryP NHH2ZWhUSU6JRWK=
HCT-116 NXjlRpBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTQdpVlUUN3ME2zMlMxOzN3IN88US=> NY\Ve4F5W0GQR1XS
G-401 M3LJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37EXWlEPTB;Mz6zOlMzOiEQvF2= MXHTRW5ITVJ?
MN-60 NVy1[FNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HrUWlEPTB;Mz60OFA6OiEQvF2= Ml7HV2FPT0WU
SW982 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHvXnRHUUN3ME2zMlUxQDR6IN88US=> NX33WWlwW0GQR1XS
RKO NGnWe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjYdGdKSzVyPUOuOVM6OzZizszN MlnjV2FPT0WU
D-283MED MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXZZotKSzVyPUOuOVc6QDZizszN NE\G[2ZUSU6JRWK=
LB996-RCC NUfWN4ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwNkK1OVgh|ryP NXTac3VJW0GQR1XS
A549 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\NOmlEPTB;Mz62N|U2OiEQvF2= NYHCdoZiW0GQR1XS
LB2241-RCC NFTWS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNwNkW3NFgh|ryP MkfiV2FPT0WU
SK-HEP-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwN{SyPVch|ryP MlX3V2FPT0WU
G-402 NFTmTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDnWnZKSzVyPUOuPFA5OzJizszN NF\uVlRUSU6JRWK=
GOTO M3LlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Lq[2lEPTB;Mz64OFM{OyEQvF2= NELwfItUSU6JRWK=
LOXIMVI NEPNZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1npfGlEPTB;Mz64OVY4PSEQvF2= M4DLcnNCVkeHUh?=
NH-12 M1vWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHRW3ZMUUN3ME20MlAyQTV7IN88US=> NX;x[WNIW0GQR1XS
CTV-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K5TmlEPTB;ND6wO|k4OyEQvF2= NXXidGliW0GQR1XS
CP50-MEL-B MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;1VGlEPTB;ND6yOFM6OiEQvF2= NYXRZ5d1W0GQR1XS
RH-18 NWjyNIxTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRwMke3NFYh|ryP NEnZOY9USU6JRWK=
NB17 NF;MdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X0fWlEPTB;ND6zNVc3QCEQvF2= MmnEV2FPT0WU
A375 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTRwM{O1NlQh|ryP NViwRmFVW0GQR1XS
IST-MES1 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvOPFJKSzVyPUSuOFE1OTFizszN NFLkRYdUSU6JRWK=
MZ2-MEL MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPyT5M6UUN3ME20MlUxOTV3IN88US=> Mk\CV2FPT0WU
CAL-54 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33T[2lEPTB;ND61N|AyQSEQvF2= MkjHV2FPT0WU
NCI-H28 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHoToRJUUN3ME20MlYzPzF5IN88US=> MnrXV2FPT0WU
D-247MG M1f0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi4OJFKSzVyPUSuO|UxPzJizszN MX\TRW5ITVJ?
NCI-H460 M4GwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHSTWM2OD12LkmxNVI4KM7:TR?= NYS4cJpPW0GQR1XS
MCF7 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT1TWM2OD13LkS0NlQ1KM7:TR?= NHXq[YpUSU6JRWK=
697 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rvT2lEPTB;NT60OFU2KM7:TR?= MWnTRW5ITVJ?
ONS-76 M4f4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvDRlFKSzVyPUWuOVcxODlizszN MVXTRW5ITVJ?
C32 NU\5WldJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTVwNkCwNlkh|ryP NEDXfm1USU6JRWK=
OS-RC-2 NV\RVlRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTVwN{O4PFch|ryP NIq5Vm9USU6JRWK=
MEL-HO NEnPcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD6TWM2OD13Lki1OlY4KM7:TR?= MmDIV2FPT0WU
LoVo NX34[5ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L3cmlEPTB;Nj6wNVYzPCEQvF2= NYXLd3RGW0GQR1XS
AGS Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfYS2I4UUN3ME22MlE1QDJ6IN88US=> M3\sRXNCVkeHUh?=
GI-ME-N MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HVUWlEPTB;Nj6yNlQzOSEQvF2= Ml3qV2FPT0WU
H-EMC-SS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Gzb2lEPTB;Nj6zPFYh|ryP M{TneXNCVkeHUh?=
RVH-421 M1HOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzvc|F6UUN3ME22MlQzPDJ6IN88US=> M1PYUnNCVkeHUh?=
SW954 M1zqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTZwNUW1O|Ih|ryP NUDGXVh{W0GQR1XS
NB5 M3rJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrPZlJIUUN3ME22MlU3OTh|IN88US=> M{n6O3NCVkeHUh?=
NCI-H2122 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7wN5VKSzVyPU[uOVg4QTNizszN MX;TRW5ITVJ?
AM-38 M1zNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfNTWM2OD14Lke1OlM6KM7:TR?= MVnTRW5ITVJ?
KNS-81-FD MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjaTHpEUUN3ME22Mlc3PDl2IN88US=> MlPUV2FPT0WU
LS-513 NEfrcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD1TWM2OD14Lke5NFI3KM7:TR?= NGfieGxUSU6JRWK=
A427 NUjaeolWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTZwOEe4Nlkh|ryP NI\MPYRUSU6JRWK=
WM-115 NX\RZYdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3RTWM2OD14LkmzNlMh|ryP NI\IWphUSU6JRWK=
COLO-829 NH:xU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTldmx[UUN3ME23MlI1OTh6IN88US=> MX;TRW5ITVJ?
NCI-H1650 NFLMS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTdwM{myNlgh|ryP MlLrV2FPT0WU
NCI-H358 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\ITWM2OD15LkS0PFc6KM7:TR?= MV3TRW5ITVJ?
HT-1080 M4fUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvqTZdRUUN3ME23MlQ5OjV2IN88US=> NHPme4FUSU6JRWK=
HCC2218 M{DsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTdwNkK5O{DPxE1? NWG4cHRWW0GQR1XS
NCI-H661 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXETWM2OD15Lki3NFY6KM7:TR?= MWTTRW5ITVJ?
KM-H2 NFnRW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n0bGlEPTB;Nz64PFY6PCEQvF2= MXTTRW5ITVJ?
RPMI-2650 M13RfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPjPFN5UUN3ME23Mlk1PDF2IN88US=> MVPTRW5ITVJ?
NCI-H226 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXRd|ZiUUN3ME24MlIyOTJ{IN88US=> NVr0WXo6W0GQR1XS
MKN45 NIq4WnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK5foE6UUN3ME24MlI3PjB{IN88US=> MUTTRW5ITVJ?
D-392MG M37zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzobVN6UUN3ME24MlUzPzJ{IN88US=> MkK2V2FPT0WU
RCC10RGB M4Lu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jvXmlEPTB;OD64OlY6PSEQvF2= NUnvXIpkW0GQR1XS
CAL-51 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvxSplkUUN3ME25MlExOjVzIN88US=> NHz5e3NUSU6JRWK=
COLO-678 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;4Z2lEPTB;OT6zNlgyOSEQvF2= MmOwV2FPT0WU
SK-MEL-24 Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i5eGlEPTB;OT61OVg2PiEQvF2= Mmr1V2FPT0WU
SK-MEL-30 NEH4XY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPvemlKSzVyPUmuPVQ1PzZizszN NUjudWJ{W0GQR1XS
MMAC-SF NXTVN3U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTFyLkO5OlEh|ryP MYfTRW5ITVJ?
NTERA-S-cl-D1 M{DJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknQTWM2OD1zMD62OVA5KM7:TR?= MnvXV2FPT0WU
NB12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXXTWM2OD1zMT61NFMh|ryP NYnX[YprW0GQR1XS
UACC-257 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rRbWlEPTB;MUGuPFY6PSEQvF2= NGnsZW9USU6JRWK=
LAN-6 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q4VWlEPTB;MUGuPVkzQCEQvF2= NH[1dpFUSU6JRWK=
SW1573 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF{LkOwPFYh|ryP MljZV2FPT0WU
NMC-G1 NVTERlJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF{LkSxO|Uh|ryP NFTRUGdUSU6JRWK=
SHP-77 NYLyNHY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrLNWhKSzVyPUGyMlU2PzRizszN NEPZUoxUSU6JRWK=
IGROV-1 NUH5PFBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHYTWM2OD1zMj62OVc{KM7:TR?= MlzmV2FPT0WU
22RV1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfqc2JMUUN3ME2xNk45ODV7IN88US=> MnzTV2FPT0WU
SK-MEL-3 M{HPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF|LkO5O|Mh|ryP MojNV2FPT0WU
NCI-H1563 M{PnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELkVHJKSzVyPUGzMlQzODJizszN M3;UfHNCVkeHUh?=
IGR-1 NFXkW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF2LkCzOFch|ryP NIDPPJBUSU6JRWK=
EW-3 M1fRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G3O2lEPTB;MUSuNVY{QSEQvF2= NH60O|BUSU6JRWK=
JEG-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ftPGlEPTB;MUSuOFk2OyEQvF2= MYDTRW5ITVJ?
ES3 M4LNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVOyXndHUUN3ME2xOE43PTZ{IN88US=> NH[2PGFUSU6JRWK=
MDA-MB-175-VII MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnlTWM2OD1zND63NVEyKM7:TR?= M4n6dnNCVkeHUh?=
P30-OHK M3H5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KxSGlEPTB;MUWuNFQ6PiEQvF2= Mn\0V2FPT0WU
GP5d Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHTXVBKSzVyPUG1MlE1PjZizszN NXS3THY6W0GQR1XS
HMV-II Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7LfpRzUUN3ME2xOU4{OzN|IN88US=> Mk\jV2FPT0WU
COLO-679 NGfQeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHEcXp{UUN3ME2xOU42ODFizszN NV;COVZqW0GQR1XS
JAR NWfSWmdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfYXI1KSzVyPUG1MlczODVizszN MUTTRW5ITVJ?
NCI-H1666 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3wR|FKSzVyPUG1Mlk{QTlizszN NX\WO|JjW0GQR1XS
SW48 NXO1S4tHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF3Lkm1NVYh|ryP M2fBOHNCVkeHUh?=
NCI-H720 NUXiRYJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH6SI5KSzVyPUG1Mlk6QDlizszN MWfTRW5ITVJ?
HT-1197 NHWxc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF4LkCzOVIh|ryP NYPhUJk6W0GQR1XS
HL-60 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF4LkCzPFQh|ryP NVm2XllPW0GQR1XS
BEN NYq4UoFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELGZnFKSzVyPUG2MlU3OzhizszN MofaV2FPT0WU
HAL-01 MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX4bo5KSzVyPUG2Mlg6ODlizszN M3vQZ3NCVkeHUh?=
SW900 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnXTWM2OD1zNj65NVMzKM7:TR?= MVLTRW5ITVJ?
SBC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnmT3R3UUN3ME2xO{42PDJ7IN88US=> M3vadXNCVkeHUh?=
SH-4 NGizbZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvubFVKSzVyPUG3MlU5PDFizszN Mom0V2FPT0WU
UACC-62 NEDJZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qzWGlEPTB;MUeuO|Y{PyEQvF2= NFTjS4hUSU6JRWK=
BHT-101 M37xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXSTWM2OD1zOT64O|A2KM7:TR?= NXrXWIFwW0GQR1XS
DB M3;ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJzLkW2OFkh|ryP M3Px[3NCVkeHUh?=
SK-MEL-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nCUWlEPTB;MkGuOVg4OiEQvF2= M1f0bnNCVkeHUh?=
NCI-H747 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTJ[3NKSzVyPUKyMlc{PzlizszN NWK3VoJWW0GQR1XS
SK-LU-1 MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HiemlEPTB;MkOuN|UzPCEQvF2= M4DtO3NCVkeHUh?=
KG-1 NWLMNYxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjvbIlKSzVyPUKzMlQ6PDZizszN NXvZS40yW0GQR1XS
LXF-289 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDRTWM2OD1{Mz63NVQh|ryP M4DJfHNCVkeHUh?=
HCC1954 NEfnTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j1V2lEPTB;MkSuPFg1PCEQvF2= NF\QTI1USU6JRWK=
Ramos-2G6-4C10 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH4NnJKUUN3ME2yOk41QThzIN88US=> MUjTRW5ITVJ?
DBTRG-05MG M4r5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJ4Lk[0PFgh|ryP NGXYXIpUSU6JRWK=
NCI-H2052 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfmS|lRUUN3ME2yO{42Pjh2IN88US=> NI[2R41USU6JRWK=
RMG-I NWG2T3FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHBR2xCUUN3ME2yPU41OTN7IN88US=> M1XuWXNCVkeHUh?=
H9 NISzWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\3[2lEPTB;M{GuN|AxQCEQvF2= NWe3fnZnW0GQR1XS
GR-ST M1;qZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HSSGlEPTB;M{KuOFQ2OyEQvF2= NELU[ItUSU6JRWK=
Mo-T MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fOemlEPTB;M{KuOVA1PiEQvF2= NVWxXW5uW0GQR1XS
SW1088 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXuTWM2OD1|Mj65PFAyKM7:TR?= NXXOUYlFW0GQR1XS
LB2518-MEL NHvkWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTN|LkC3PVch|ryP NV3mPWlxW0GQR1XS
NCI-H82 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXoUndjUUN3ME2zN{4yPjZzIN88US=> Mm\xV2FPT0WU
LAMA-84 NGnGcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmzTWM2OD1|ND62NFc{KM7:TR?= NX[0fWRJW0GQR1XS
KYSE-450 NEOxcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLITGh[UUN3ME2zOE43Pzd4IN88US=> NIC5SmtUSU6JRWK=
LU-99A M3rYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN3LkCwNFch|ryP NXfqdFg{W0GQR1XS
BE-13 NILlNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTN3Lk[1OFUh|ryP MYDTRW5ITVJ?
GAK M1e4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPoSmlKSzVyPUO1MlY6PSEQvF2= MlvwV2FPT0WU
NCI-H1573 NYPhZ2dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPQVGdKSzVyPUO1Mlg5OThizszN M{PoXHNCVkeHUh?=
AsPC-1 M4O5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq4fItDUUN3ME2zOk4yPTJ5IN88US=> NXu5RopIW0GQR1XS
HDLM-2 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT0TWM2OD1|Nj6zNVYh|ryP M3nv[HNCVkeHUh?=
NCI-H441 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\5eoF2UUN3ME2zO{4xPjlzIN88US=> MXjTRW5ITVJ?
CAL-27 NUnWZ4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN5LkeyN|Eh|ryP MmHBV2FPT0WU
OVCAR-3 NXywSHFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT0dnBbUUN3ME2zPU4{OThzIN88US=> NE\VeGVUSU6JRWK=
RPMI-8226 M161c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN7LkW5PEDPxE1? NXfJR21GW0GQR1XS
EFO-21 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jYT2lEPTB;NECuOVgyPCEQvF2= Mk\sV2FPT0WU
SNU-C2B NVPyXIM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[xOWlEPTB;NEGuOVA5PCEQvF2= MXPTRW5ITVJ?
VM-CUB-1 NHrSZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3kXnFKSzVyPUSzMlgxOzdizszN NWnYeXVQW0GQR1XS
NCI-H2087 NHvNNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr0ZoZKSzVyPUS1MlAzOzNizszN MYHTRW5ITVJ?
EW-16 NITLUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR4LkOxN|ch|ryP MmX3V2FPT0WU
SK-N-AS M2C0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnrTXB[UUN3ME20Ok44OTZ5IN88US=> NXrxZ5dkW0GQR1XS
COR-L105 NVS2fFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTR4Lki4OVch|ryP MWjTRW5ITVJ?
DEL MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33ZS2lEPTB;NEiuNFQzQSEQvF2= NH\2ZmVUSU6JRWK=
JVM-2 M3nVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P4O2lEPTB;NEiuNFU2QCEQvF2= M3\hPHNCVkeHUh?=
KARPAS-45 NX7TV|lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD5TWM2OD12OT60OVM5KM7:TR?= MUXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID